Are you the publisher? Claim or contact us about this channel


Embed this content in your HTML

Search

Report adult content:

click to rate:

Account: (login)

More Channels


Showcase


Channel Catalog


Channel Description:

Visit One News Page for Veterans news from around the world, aggregated from leading sources including newswires, newspapers and broadcast media. Search millions of archived news headlines. This feed provides the Veterans news headlines.

older | 1 | .... | 1326 | 1327 | (Page 1328) | 1329 | 1330 | .... | 1362 | newer

    0 0

    Based on the Ancient Native American Legend About the Origin of the Crow, the John Legend Executive-Produced Animated Short is Now Widely Available Online

    LOS ANGELES (PRWEB) November 15, 2018

    Baobab Studios proudly announced today the official global release of “Crow: The Legend”. This award-winning story is now widely available online to consumers for the first time, offered as a traditional animated short film (http://bit.ly/2RX73ZP) as well as an interactive virtual reality experience free to download within the Oculus Store  (https://ocul.us/2RX9QSR)

    Released in conjunction with Native American Heritage Month, “Crow: The Legend” is based on the poignant Native American legend about the bird’s cultural genesis and is the first of its kind to incorporate an indigenous worldview, according to Sarah Eagle Heart, CEO of Native Americans in Philanthropy, cultural advisor, and voice of "Luna" in "Crow". Through a partnership with Native Americans in Philanthropy (https://nativephilanthropy.org), Baobab Studios aims to brings heightened awareness to culturally-important stories like "Crow", that have for so long lacked a major platform.
     
    Randy Edmonds, respected 84-year-old Kiowa-Caddo tribal elder and founder of the National Indian Urban Council, who voices "Narrator" in "Crow" explains, "All Native American tales have a tradition of deep meaning and that’s why we tell the stories, sharing down the generations. When I look at the impact these legends have, the insights they represent, taking that storytelling to a modern medium is extremely exciting. The beautiful work being created -inspired by our folklore- is like nothing I’ve ever experienced in my many years.”
     
    Crow, once the most revered animal in all the forest with his colorful plumage and melodic voice, must choose between himself and his fellow animals when tasked with saving them from a destructive endless winter. Realizing he is their only hope, Crow ventures in seek of help but the arduous trek irrevocably damages his voice and stunning colors. Embarrassed by his physical transformation, Crow ultimately learns that his self-sacrifice is far more beautiful and important than his appearance.  
     
    “We are excited about the opportunity to honor the Native American storytelling tradition and to share Indigenous worldview with the passionate support of Native Americans in Philanthropy. By making both versions available, we are now able to share this powerful tale with audiences everywhere and give viewers the opportunity decide how to participate in Crow’s journey in this holistic animation experience”, said Baobab co-founder and "Crow" producer, writer and director Eric Darnell (“Madagascar” franchise, “Antz”).
     
    Native Americans in Philanthropy CEO Sarah Eagle Heart added, “The film released in both VR and 2D allows a mainstream audience to celebrate stories from the wildly underrepresented Native American community in Hollywood. I could not be happier that these films are available during Native American Heritage Month, which pays homage to the rich culture that indigenous people share.”
     
    Featuring an original song by Executive-Producer John Legend, the project contains a diverse all-star cast of voice talent including: Legend as Crow; Oprah Winfrey who makes her VR debut as The One Who Creates Everything By Thinking; Sarah Eagle Heart (Native Americans in Philanthropy CEO) as Luna, a character named after Legend’s daughter; Kiowa-Caddo Tribal Elder and lifelong Native rights crusader Randy Edmonds as Narrator; Liza Koshy (Liza on Demand) as Owl; Diego Luna ("Narcos") as Moth; Tye Sheridan ("Ready Player One") as Turtle; and Constance Wu ("Crazy Rich Asians", "Fresh Off the Boat") as Skunk.
     
    For more information about “Crow: The Legend” or to learn more about Baobab Studios please visit http://www.baobabstudios.com/crow

    For press inquiries, please contact Alex Martinetti: amartinetti@rogersandcowan.com

    About Baobab Studios
    Two-time Emmy award winning Baobab Studios is the world’s leading independent immersive animation studio. Founded by Eric Darnell (Co-Director of all 4 Madagascar films), the multi-award winning company won a second Emmy for the critically-acclaimed ASTEROIDS!, starring Elizabeth Banks and Ingrid Nilsen at the 2018 Emmy Awards. 

    Baobab is also responsible for the Emmy-winning VR animation, INVASION!, starring Ethan Hawke which holds the record for most downloaded VR app in history.  Roth Kirschenbaum Films (Maleficent, Alice in Wonderland, Snow White and the Huntsman) is slated to adapt INVASION! into an upcoming feature film. In addition to Crow: The Legend, Baobab debuted Jack at the 2018 Tribeca Film Festival, an interactive animation based on Jack and the Beanstalk, starring Lupita Nyongo. 

    Baobab Studios was founded in 2015 by industry veterans Eric Darnell, Larry Cutler, and Maureen Fan, and has raised more than $31 million in venture capital backing.  Lauded as the “Pixar of Virtual Reality” (CNet, The Wall Street Journal), Baobab’s executives hail from the leading lights of Fox Animation, Blizzard, Zynga, DreamWorks, and Pixar.  The company’s advisors include Alvy Ray Smith (co-founder of Pixar), Glenn Entis (DreamWorks Animation co-founder), legendary Oscar-winning animator Glenn Keane, Mireille Soria (DreamWorks Animation Co-President), David Anderman (former Lucasfilm COO), Kevin Lin (Twitch co-founder), Jane Rosenthal (Co-founder Tribeca Enterprises), Bing Chen (former YouTube Global Head of Creator Development & Management), Jasmine Madatian (former EVP Comms, Amblin/Dreamworks), and Chris Milk (VR Innovator). Reported by PRWeb 14 hours ago.

    0 0

    Leading companies and individuals to be recognized at Dec. 3 event

    HERNDON, Va. (PRWEB) November 15, 2018

    The Northern Virginia Technology Council (NVTC) today announced the companies and executives selected for the inaugural NVTC Tech 100.

    NVTC Tech 100 companies and individuals are driving tech innovation, implementing new solutions for their customers, and leading growth in the Greater Washington region. The Tech 100 will be celebrated at an exclusive party at the Ritz-Carlton, Tysons Corner on December 3, 2018.

    Nominations received were reviewed by a judging committee and the following companies and individuals have been selected:

    2018 Tech 100 Companies

    AbleVets LLC                    
    AboutWeb
    All Traffic Solutions
    Altamira Technologies
    Altum, Inc.
    Amazon Web Services
    AMLLC
    ANRA Technologies
    Aperiomics, Inc.
    AppTek
    Aquicore
    ArdentMC
    Arterra
    B3 Group
    Binary Fountain
    Blue Ridge Networks
    Booz Allen Hamilton
    Bricata
    ByteCubed
    CALIBRE Systems, Inc.
    ChurnZero
    Cognosante
    Compass
    Confident Governance
    CVP
    Cyber Apex Solutions
    Cyxtera Federal Group        
    Decisiv
    Deltek
    DH Tech
    Digital Realty
    Dovel Technologies
    E-Agree
    Federated Wireless
    Forcepoint
    Fractal Industries
    Fugue
    Giant Oak
    GoCanvas
    HomeCare.com
    ICF
    IntelliDyne, LLC
    INVOKE
    IronNet Cybersecurity
    LifeCents
    LookingGlass Cyber Solutions
    MicroHealth, LLC
    Mobile Posse
    NET ESolutions (NETE)
    Noctil
    Northrop Grumman Corporation
    NTT DATA
    Octo
    Patrocinium Systems
    Peraton
    Perfecta
    Perspecta
    Phone2Action
    PockitShip, Inc.
    Power Distribution Inc.
    Qlarion
    QTS
    RagingWire Data Centers
    Resonate
    RIVA Solutions
    Roqos, Inc.
    SAIC
    Samsung Electronics
    ScienceLogic
    ScientiaMobile
    Senseware
    Siemens Government Technologies, Inc.
    Simulyze
    SOC Telemed
    Square Peg Technologies
    Status Identity
    ThreatQuotient
    ThreatSwitch
    Transaction Network Services (TNS)
    TwoSixLabs
    Unanet
    ViON
    Virid
    WireWheel
    Wize Solutions

    2018 Tech 100 Executives

    Megan Anderson, In-Q-Tel
    Craig Bandes, Pixelligent
    Greg Baroni, Attain, LLC
    Judy Bjornaas, ManTech
    Matthew Calkins, Appian
    Fran Craig, Unanet
    Ken Fang, Mobomo, LLC
    Ryan LaSalle, Accenture
    Maribeth Luftglass, Fairfax County Public Schools
    Michael Maiorana, Verizon
    Carolyn Parent, LiveSafe
    Erich Sanchack, Digital Realty
    Stu Shea, Peraton
    Toni Townes-Whitley, Microsoft
    Lev Volftsun, Sestra Systems
    Josh Wilson, LMI
    John B. Wood, Telos Corporation

    The Northern Virginia Technology Council (NVTC) is the membership and trade association for the technology community in Northern Virginia. As the largest technology council in the nation, NVTC serves about 1,000 companies from all sectors of the technology industry, as well as service providers, universities, foreign embassies, nonprofit organizations and governmental agencies. Through its member companies, NVTC represents about 300,000 employees in the region. NVTC is recognized as the nation's leader in providing its technology community with networking and educational events; specialized services and benefits; public policy advocacy; branding of its region as a major global technology center; initiatives in targeted business sectors and in the international, entrepreneurship, workforce and education arenas; and the NVTC Foundation, a 501(c)(3) nonprofit charity that supports the NVTC Veterans Employment Initiative and other priorities within Virginia's technology community. Visit NVTC at http://www.nvtc.org Reported by PRWeb 14 hours ago.

    0 0

    Our patriotic veterans have given their lives in defense of the United States in all kinds of weather. Today, these veterans are rolling over in their graves. My uncle Oscar, a veteran of WWI, is surely one of them. Curtis Charnell Bondurant, Poulsbo, U.S. Navy, retired Reported by Seattle Times 13 hours ago.

    0 0

    It was a salute to female members of the U.S. military. A cosmetics company teamed up with veterans groups to make them feel extra special, giving them spa services for their sacrifice. Reported by CBS 2 13 hours ago.

    0 0

    Ancient Indian discipline used by The Beatles can be practised at home and may be a helpful alternative to most widely used therapy where soldiers are coached to relive combat experiences Reported by Independent 12 hours ago.

    0 0

    Days after he was criticized for canceling a trip to a WWI cemetery in Paris and not visiting Arlington National Cemetery on Veterans Day, President Donald Trump honored the nation's veterans and touted his administration's commitment. (Nov. 15)

     
     
     
     
     
     
      Reported by USATODAY.com 12 hours ago.

    0 0

    At a hearing Thursday, members of Congress grilled VA officials about delays in GI Bill payments to veterans Reported by CBS News 12 hours ago.

    0 0

    The Department of Veterans Affairs said Thursday it's trying to speed up benefits payments to thousands of veterans who are struggling to cover their education and housing bills. The delays are being blamed on IT issues. CBS News national correspondent Chip Reid reports. Reported by CBS News 12 hours ago.

    0 0

    November 12 private screening of “First Man,” based on the biography of former Navy aviator and astronaut Neil Armstrong, continues the annual tradition of a free movie night for vets as part of Veterans Week NYC 2018, a week’s celebration surrounding Veterans Day.

    NEW YORK (PRWEB) November 15, 2018

    Veterans Advantage, PBC, together with IMAX Corporation (NYSE: IMAX), proudly announces a free, private IMAX movie screening of the Universal Pictures’ “First Man” in honor of Veterans Day.

    The Monday, November 12 private screening is available for military, veterans and their family members, including Veterans Advantage VetRewards Card holders. The film stars Ryan Gosling (“La La Land”) as Neil A. Armstrong, the first man to set foot on the moon. Armstrong had also been a U.S. Navy aviator earlier in his career. The film is directed by Academy Award® winner Damien Chazelle (“La La Land,” “Whiplash”), and co-stars Claire Foy (Netflix’s “The Crown”) as Neil’s wife, Janet Armstrong.

    Sponsored by IMAX, the private screening will be shown at 7 pm at the AMC Loews 34th Street at 312 West 34th Street, as part of Veterans Week NYC 2018. Attending veterans and their families will be offered free popcorn, soft drinks and goodie bags from IMAX, plus special prize giveaways.

    "Our movie screenings have been very much appreciated by veterans and their families year after year thanks to the tremendous generosity of IMAX, and, once again, IMAX has committed to thanking our veterans with a top-notch motion picture,” said Scott Higgins, Co-Founder and CEO of Veterans Advantage. Higgins is also one of the founding partners of Veterans Week NYC. “We expect our members and fellow veterans to have a great night of entertainment and an opportunity to connect with each other.”

    Over the past several years, IMAX and Veterans Advantage have held special Veterans Day private screenings such as “Dear America: Letters Home from Vietnam,” “Lone Survivor,” starring Mark Wahlberg as Navy SEAL Marcus Luttrell, “Unbroken,” the biopic of WWII prisoner of war Louis Zamperini, “Sully,” about the heroic Hudson River plane landing by pilot Chesley Sullenberger, and most recently the Oscar-winning World War II drama “Dunkirk.”

    "We are honored to be once again part of this fine tradition of honoring our veterans and families with top quality IMAX movies on Veterans Week," IMAX CEO Richard Gelfond said. “We are grateful Veterans Advantage continues to advocate for our most deserving of Americans in partnering with us for these special events, and reaching out to the veterans community on our behalf.”

    Veterans Advantage is a proud presenting sponsor of Veterans Week NYC 2018 and that its VetRewards Card, a national military ID, is the Official Card of Veterans Week NYC. Also in the spirit of the patriotic holiday, Veterans Advantage is giving 50% OFF on its exclusive benefits program, which includes the VetRewards Card for redemption of hundreds of military discounts and savings from top retailers and leading travel providers nationwide. http://www.veteransadvantage.com

    About “First Man”
    On the heels of their six-time Academy Award®-winning smash, La La Land, Oscar®-winning director Damien Chazelle and star Ryan Gosling reteam for Universal Pictures’ First Man, the riveting story behind the first manned mission to the moon, focusing on Neil Armstrong and the decade leading to the historic Apollo 11 flight. A visceral and intimate account told from Armstrong’s perspective, based on the book by James R. Hansen, the film explores the triumphs and the cost—on Armstrong, his family, his colleagues and the nation itself—of one of the most dangerous missions in history.

    Written by Academy Award® winner Josh Singer (Spotlight, The Post), the epic drama of leading under the pressure of grace and tragedy is produced by Wyck Godfrey & Marty Bowen (The Twilight Saga, The Fault in Our Stars) through their Temple Hill Entertainment banner, alongside Isaac Klausner (Love, Simon) and Chazelle. Steven Spielberg, Adam Merims and Singer executive produce, while DreamWorks Pictures co-finances the film. http://www.firstman.com Reported by PRWeb 12 hours ago.

    0 0

    Meditation worked as well as traditional therapy for military veterans with post-traumatic stress disorder in a small experiment sponsored by the Department of Defense. One method preferred by the Department of Veterans Affairs is exposure therapy, but it doesn't work for everyone and many can't handle what it requires: purposely recalling traumatic events and confronting emotions. Meditation could be a better choice for some, the researchers said. The experiment tested meditation against exposure therapy, which involves working with a therapist and gradually letting go of fears triggered by painful memories. Reported by SeattlePI.com 11 hours ago.

    0 0

    Players still talk trash to each other on game days in the NFL, but maybe not as much as they used to. The Cardinals' Patrick Peterson still hears it.

     
     
     
     
     
     
     
      Reported by azcentral.com 7 hours ago.

    0 0

    DGAP-News: Biofrontera AG / Key word(s): 9-month figures

    16.11.2018 / 08:05
    The issuer is solely responsible for the content of this announcement.
    --------------------

    *Biofrontera reports earnings results for the third quarter and first nine months of 2018*

    *Leverkusen, Germany, November 16, 2018* - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2018 and provided an update on recent developments.

    · Total revenue increased 98% to approximately EUR 14.6 million for the first nine months of 2018, compared to approximately EUR 7.3 million in the same period 2017.
    · Product revenue increased 131% to approximately EUR 14.4 million for the first nine months of 2018, compared to approximately EUR 6.2 million in the same period 2017.
    · Net loss was approximately EUR 12.3 million or 0.28 per share for the first nine months of 2018, compared to approximately EUR 14.6 million or 0.38 per share in the same period 2017.
    · Raised revenue guidance for the current year from EUR 16 to 20 million to EUR 19 to 22 million in October 2018.
    · Award of a five-year contract with the U.S. Department of Veterans Affairs in August 2018.
    · Approval of Ameluz^(R) in combination with daylight photodynamic therapy (PDT) by the European Commission in March 2018 and in Switzerland in September 2018.
    · Completion of patient recruitment for the Phase III trial of Ameluz^(R) / BF-RhodoLED^(R) for the treatment of actinic keratoses on the extremities or trunk/neck in July 2018.
    · Start of patient recruitment for the U.S. Phase III trial evaluating Ameluz^(R) / BF-RhodoLED^(R) for superficial basal cell carcinoma in September 2018.

    "Through the successful implementation of our strategy, we have further improved the positioning and market potential of Ameluz^(R), which allowed us to record a significant increase in sales in the first nine months of this year", says Prof. Dr. Hermann Lübbert, CEO of Biofrontera. "We achieved and even exceeded our operational goals in the reporting period. Ameluz^(R) has increasingly been turning into a household name among dermatologists, especially in the United States. This and the significant improvement in reimbursement for physicians through the J-code as well as the revised CPT-codes for photodynamic therapy led to a constant increase in U.S. sales. In the third quarter, the anticipated 5.6% increase in the list price to US$ 285 on October 1st, led to more purchases by U.S. customers. Daylight-PDT fueled the PDT market in Europe. As a result, September marks a global sales record for Ameluz^(R) with more than 22,000 tubes sold", comments Prof. Dr. Hermann Lübbert.

    *Key financial figures for the first nine months 2018:*

    *In EUR thousands, except where noted* *9M 2018
    unaudited* *9M 2017
    unaudited* *Change *
    Revenue 14,552 7,334 98%
    from product sales
    14,383 6,238 131%
    from development projects
    129 1,096 -88%
    other
    40 NA
    Research and development costs (3,219) (3,233) 0%
    General administrative costs (7,283) (3,626) -101%
    Sales costs (12,658) (12,586) -1%
    Net loss (12,253) (14,614) 16%
    Earnings per share (in EUR) (0,28) (0,38) 26%

     

    Biofrontera generated total revenue of approximately EUR 14.6 million in the first nine months of 2018, representing 98% year-over-year growth. In the U.S., revenues increased 204% during the reporting period to EUR 10.2 million, compared to the same period 2017. Sales in Germany improved to EUR 2.1 million, representing a 24% increase compared to the previous year. Revenue in the remainder of Europe amounted to EUR 2.1 million, an increase of 73% compared to the same period last year.

    Gross profit on sales improved by EUR 5.3 million in the reporting period to EUR 11.8 million compared to EUR 6.4 million in the same period last year. The gross margin fell from 88% in the first nine months of 2017 to 81% in the first nine months of 2018. This is due to a significant reduction in revenues from other regions/development projects, which were not offset by any cost of sales in the prior-year period.

    The consolidated net loss for the nine months of 2018 was EUR -12.3 million, or EUR -0.28 per share, compared to the net loss of EUR -14.6 million, or EUR -0.38 in the same period last year.

    Cash and cash equivalents were EUR 21.1 million as of September 30, 2018, compared to EUR 11.1 million as of December 31, 2017.

    In view of the latest business development, Biofrontera AG has in October raised its revenue guidance for the current year from EUR 16 to 20 million to EUR 19 to 22 million, while the forecast for the consolidated net loss in 2018 remains unchanged at EUR 15 to EUR 16 million.

    *U.S. Commercial Update*

    The U.S. continues to be the largest growth market. In the first nine months of 2018, sales revenue in the U.S. totaled EUR 10.2 million, a 204% increase compared to the same period last year. The significant improvement in the reimbursement of medical expenses through the J-code and the revised CPT-codes led to a consistent increase in sales to U.S. customers. Additionally, U.S. revenue was supported in the third quarter by an anticipatory effect due to the expected 5.6% increase in the list price as of October 1. Another milestone in the last quarter was the award of a five-year contract with the U.S. Department of Veterans Affairs in August 2018, which enables us to offer Ameluz^(R) to all medical facilities of the U.S. Department of Veterans Affairs and the U.S. Department of Defense.

    *EU Commercial Update*

    Biofrontera reported a 73% increase in revenues in all our European markets (excluding Germany) in the first nine months of 2018 as compared to the same period in 2017. With the European Commissions' approval for treatment with daylight photodynamic therapy (PDT) for actinic keratosis, Ameluz^(R) has become more competitive against existing PDT drugs, as well as patient-applied topical treatments. In Germany, our largest EU market, the reimbursement status of Ameluz^(R) improved significantly with the approval of Ameluz^(R) in combination with daylight-PDT. As a result, in the entire reporting period, the Company recorded a substantial increase of 24% to EUR 2.1 million in sales in Germany, which was mostly due to the summer months. In addition, following the introduction of Ameluz^(R) in combination with daylight-PDT, we experience an expansion of the entire PDT market.

    *Clinical Update*

    In July 2018, Biofrontera announced that it had completed patient recruitment for its ongoing phase III trial of Ameluz^(R) and BF-RhodoLED^(R) for the treatment of actinic keratoses on the extremities, trunk and neck. The Company expects further growth in the market potential from the study and anticipates the results in the first quarter of 2019. After successful approval, Ameluz^(R) would be the only PDT drug in Europe and the U.S. that can be used to treat actinic keratoses of all degrees of severity on the extremities, as well as the torso and neck.

    In order to further increase our growth opportunities in the U.S. market in the medium term, Biofrontera is currently conducting a phase III trial evaluating the treatment of superficial basal cell carcinoma (BCC) with Ameluz^(R) in combination with its BF-RhodoLED^(R) lamp in the United States, for which patient recruitment started in September 2018. Study results are anticipated to be available in the first half of 2020. Following successful FDA approval, Ameluz^(R) would be the only drug in the U.S. for the treatment of superficial BCC through PDT. This would allow the Company to offer patients and physicians a treatment option for BCC with high efficacy and excellent cosmetic results.

    *Conference Call*

    Conference calls for shareholders and interested investors will be held on November 16, 2018 at the following times:

    In German, at 10:00 am CEST (4:00 am EDT)
    Dial-in number Germany: +49 (0) 69201744220
    Conference code: 14005835#

    In English, at 2:00 pm CEST (8:00 am EDT)
    Dial-in number USA: +1 8774230830
    Dial-in number UK: +44 2030092470
    Conference code: 12331554#

    Please dial in 5 minutes ahead of time to ensure a timely start of the conference call.

    The Company's half-year report including financial statements is available at
    www.biofrontera.com/en/investors/financial-reports.

    *-End-*

     

    *For enquiries, please contact:

    Biofrontera AG *
    Thomas Schaffer, Chief Financial Officer

    +49 (0) 214 87 63 2 0
    ir@biofrontera.com
    *IR UK: Seton Services *
    Toni Vallen
    +44 (0) 207 224 8468
    *IR and PR US: The Ruth Group*
    IR: Tram Bui
    PR: Kirsten Thomas
    +1 646-536-7035
    +1 508-280-6592

     

    *About Biofrontera:*

    Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.

     

    *Forward Looking Statements:*

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate,""believe,""forecast,""estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.
    --------------------

    16.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.dgap.de --------------------

    Language: English
    Company: Biofrontera AG
    Hemmelrather Weg 201
    51377 Leverkusen
    Germany
    Phone: +49 (0)214 87632 0
    Fax: +49 (0)214 87632 90
    E-mail: ir@biofrontera.com
    Internet: www.biofrontera.com
    ISIN: DE0006046113, NASDAQ: BFRA
    WKN: 604611
    Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq
     
    End of News DGAP News Service Reported by EQS Group 5 hours ago.

    0 0

    Leverkusen, Germany, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the nine months ended September 30, 2018 and provided an update on recent developments.· Total revenue increased 98% to approximately EUR 14.6 million for the first nine months of 2018, compared to approximately EUR 7.3 million in the same period 2017.
    · Product revenue increased 131% to approximately EUR 14.4 million for the first nine months of 2018, compared to approximately EUR 6.2 million in the same period 2017.
    · Net loss was approximately EUR 12.3 million or 0.28 per share for the first nine months of 2018, compared to approximately EUR 14.6 million or 0.38 per share in the same period 2017.
    · Raised revenue guidance for the current year from EUR 16 to 20 million to EUR 19 to 22 million in October 2018.
    · Award of a five-year contract with the U.S. Department of Veterans Affairs in August 2018.
    · Approval of Ameluz^® in combination with daylight photodynamic therapy (PDT) by the European Commission in March 2018 and in Switzerland in September 2018.
    · Completion of patient recruitment for the Phase III trial of Ameluz^® / BF-RhodoLED^® for the treatment of actinic keratoses on the extremities or trunk/neck in July 2018.
    · Start of patient recruitment for the U.S. Phase III trial evaluating Ameluz^® / BF-RhodoLED^® for superficial basal cell carcinoma in September 2018.

    „Through the successful implementation of our strategy, we have further improved the positioning and market potential of Ameluz^®, which allowed us to record a significant increase in sales in the first nine months of this year”, says Prof. Dr. Hermann Lübbert, CEO of Biofrontera. „We achieved and even exceeded our operational goals in the reporting period. Ameluz^® has increasingly been turning into a household name among dermatologists, especially in the United States. This and the significant improvement in reimbursement for physicians through the J-code as well as the revised CPT-codes for photodynamic therapy led to a constant increase in U.S. sales. In the third quarter, the anticipated 5.6% increase in the list price to US$ 285 on October 1st, led to more purchases by U.S. customers. Daylight-PDT fueled the PDT market in Europe. As a result, September marks a global sales record for Ameluz^® with more than 22,000 tubes sold”, comments Prof. Dr. Hermann Lübbert.

    *Key financial figures for the first nine months 2018:*

    *In EUR thousands, except where noted* *9M 2018*
    *unaudited* *9M 2017*
    *unaudited* *Change *
    Revenue 14,552   7,334   98 %
      from product sales 14,383   6,238   131 %
      from development projects 129   1,096   -88 %
      other 40     NA
    Research and development costs (3,219 ) (3,233 ) %
    General administrative costs (7,283 ) (3,626 ) -101 %
    Sales costs (12,658 ) (12,586 ) -1 %
    Net loss (12,253 ) (14,614 ) 16 %
    Earnings per share (in EUR) (0,28 ) (0,38 ) 26 %

    Biofrontera generated total revenue of approximately EUR 14.6 million in the first nine months of 2018, representing 98% year-over-year growth. In the U.S., revenues increased 204% during the reporting period to EUR 10.2 million, compared to the same period 2017. Sales in Germany improved to EUR 2.1 million, representing a 24% increase compared to the previous year. Revenue in the remainder of Europe amounted to EUR 2.1 million, an increase of 73% compared to the same period last year.

    Gross profit on sales improved by EUR 5.3 million in the reporting period to EUR 11.8 million compared to EUR 6.4 million in the same period last year. The gross margin fell from 88% in the first nine months of 2017 to 81% in the first nine months of 2018. This is due to a significant reduction in revenues from other regions/development projects, which were not offset by any cost of sales in the prior-year period.

    The consolidated net loss for the nine months of 2018 was EUR -12.3 million, or EUR -0.28 per share, compared to the net loss of EUR -14.6 million, or EUR -0.38 in the same period last year.

    Cash and cash equivalents were EUR 21.1 million as of September 30, 2018, compared to EUR 11.1 million as of December 31, 2017.

    In view of the latest business development, Biofrontera AG has in October raised its revenue guidance for the current year from EUR 16 to 20 million to EUR 19 to 22 million, while the forecast for the consolidated net loss in 2018 remains unchanged at EUR 15 to EUR 16 million.

    *U.S. Commercial Update*

    The U.S. continues to be the largest growth market. In the first nine months of 2018, sales revenue in the U.S. totaled EUR 10.2 million, a 204% increase compared to the same period last year. The significant improvement in the reimbursement of medical expenses through the J-code and the revised CPT-codes led to a consistent increase in sales to U.S. customers. Additionally, U.S. revenue was supported in the third quarter by an anticipatory effect due to the expected 5.6% increase in the list price as of October 1. Another milestone in the last quarter was the award of a five-year contract with the U.S. Department of Veterans Affairs in August 2018, which enables us to offer Ameluz^® to all medical facilities of the U.S. Department of Veterans Affairs and the U.S. Department of Defense.

    *EU Commercial Update*

    Biofrontera reported a 73% increase in revenues in all our European markets (excluding Germany) in the first nine months of 2018 as compared to the same period in 2017. With the European Commissions’ approval for treatment with daylight photodynamic therapy (PDT) for actinic keratosis, Ameluz^® has become more competitive against existing PDT drugs, as well as patient-applied topical treatments. In Germany, our largest EU market, the reimbursement status of Ameluz^® improved significantly with the approval of Ameluz^® in combination with daylight-PDT. As a result, in the entire reporting period, the Company recorded a substantial increase of 24% to EUR 2.1 million in sales in Germany, which was mostly due to the summer months. In addition, following the introduction of Ameluz^® in combination with daylight-PDT, we experience an expansion of the entire PDT market.

    *Clinical Update*

    In July 2018, Biofrontera announced that it had completed patient recruitment for its ongoing phase III trial of Ameluz^® and BF-RhodoLED^® for the treatment of actinic keratoses on the extremities, trunk and neck. The Company expects further growth in the market potential from the study and anticipates the results in the first quarter of 2019. After successful approval, Ameluz^® would be the only PDT drug in Europe and the U.S. that can be used to treat actinic keratoses of all degrees of severity on the extremities, as well as the torso and neck.

    In order to further increase our growth opportunities in the U.S. market in the medium term, Biofrontera is currently conducting a phase III trial evaluating the treatment of superficial basal cell carcinoma (BCC) with Ameluz^® in combination with its BF-RhodoLED^® lamp in the United States, for which patient recruitment started in September 2018. Study results are anticipated to be available in the first half of 2020. Following successful FDA approval, Ameluz^® would be the only drug in the U.S. for the treatment of superficial BCC through PDT. This would allow the Company to offer patients and physicians a treatment option for BCC with high efficacy and excellent cosmetic results.

    *Conference Call*

    Conference calls for shareholders and interested investors will be held on November 16, 2018 at the following times:

    In German, at 10:00 am CEST (4:00 am EDT)
    Dial-in number Germany: +49 (0) 69201744220
    Conference code: 14005835#

    In English, at 2:00 pm CEST (8:00 am EDT)
    Dial-in number USA: +1 8774230830
    Dial-in number UK: +44 2030092470
    Conference code: 12331554#

    Please dial in 5 minutes ahead of time to ensure a timely start of the conference call.

    The Company’s half-year report including financial statements is available at
    www.biofrontera.com/en/investors/financial-reports.

    *About Biofrontera:*

    Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at www.biofrontera.com.

    *Forward Looking Statements:*

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate,""believe,""forecast,""estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports filed with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.

    *For enquiries, please contact: *

    *Biofrontera AG *

    Thomas Schaffer, Chief Financial Officer  

    +49 (0) 214 87 63 2 0

    ir@biofrontera.com *IR UK: Seton Services *

    Toni Vallen  

    +44 (0) 207 224 8468 *IR and PR US: The Ruth Group*

    IR: Tram Bui

    PR: Kirsten Thomas  

    +1 646-536-7035

    +1 508-280-6592 Reported by GlobeNewswire 5 hours ago.

    0 0

    LOS ANGELES, CA, Nov. 16, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Geopulse Exploration, Inc. (OTC PINK: GPLS), DBA Cannco Brands (“Geopulse”), a blockchain-based logistics, trade finance and promotion ecosystem for the cannabis sector is pleased to announce that it will be presenting at the Emerging Manager Forum -  “Crypto Day”.

    The event is today at the Fairmont Hotel in San Francisco. The agenda includes presentations and panels from the leaders in the emerging crypto and blockchain industries.

    The event is hosted by Applicature, Inc. (www.applicature.com). The Geopulse/Cannco is working with Applicature as ICO consultants, with extensive experience in blockchain projects and cryptocurrency ICO’s in relevant fields, including banking, mobile payments, supply chain logistics, and even cannabis tech.

    Applicature will be assisting the Company with designing and testing our token economic structure, liquidity and stability models, Whitepaper and ICO investment documents, as well as numerous other aspects for its ICO preparation.  Their team will simultaneously be developing both the initial smart contracts, as well as ICO “Contribution Cabinet”, which a suite of applications, API’s and widgets which will allow participants the world over to invest directly in the ICO using Ethereum, Bitcoin, fiat currency, credit cards, and ACH.  Applicature has assisted and/or managed over 25 successful ICO’s for their clients, so Cannco is extremely excited to be working with them.

    The Cannco team is looking forward to meeting the attendees at the conference as well as work directly with the Applicature team which has convened from offices around the world for this event. The agenda for the event is here: https://finance.knect365.com/hedge-fund-emerging-and-startup-manager-forum-west-coast-usa-conference...#

    The Technology team has also been working aggressively at designing our MVP (minimum viable product) for the blockchain space, with the hope of deploying an alpha version of our core services soon, for testing by key industry participants.  

    The Company recommends that interested parties follow our twitter feed @cannco.network, for updates on our developing business relationships within the industry.  Management has been getting wonderful feedback on our strategy and message and are looking forward to working with respected brands and supply chain partners who’ve been eager to participate in the development process.

    About Geopulse, DBA Cannco Brands

    Geopulse (OTC PINK: GPLS) develops a blockchain-powered logistics, financial services and promotion platform for the unbanked, early stage and explosive growth U.S. and Canadian cannabis sector. Management is comprised of tech and finance veterans with strong product management experience. Among its assets (or pending acquisitions) are THCFinder.com, 300,000 user geo-finder app for cannabis dispensaries and MMJ medical offices throughout the US; CannCoin, a native token underlying a distributed ledger logistics and financial services ecosystem for cannabis; revenue generating StonerDays.com, an online D2C lifestyle community with 700,000 followers. Cannco Brands intends to provide the commercial services such as transparent supply chain management, business banking and merchant processing, trade finance, direct-to-consumer engagement solutions.

    Safe Harbor Notice

    Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Geopulse Exploration, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Geopulse Exploration, Inc. undertakes no obligation to revise these statements following the date of this news release.

    CONTACT: Marcus Laun
    CEO
    Corporate telephone: (323) 300-4550
    6600 Sunset Blvd., 2nd Floor
    Los Angeles, CA 90028 Reported by GlobeNewswire 3 hours ago.

    0 0

    Meditation eases PTSD in veterans suffering from flashbacks, nightmares and insomnia  Researchers from the US Department of Veterans Affairs, Washington DC, found that 61 per cent of veterans with PTSD saw their symptoms improve just three months after starting meditation. Reported by MailOnline 3 hours ago.

    0 0

    The CoWrks Foundry announced the completion of its first cohort, comprising of five innovative startups today. The program is designed to nurture early-stage startups in the field of Urban Tech, Enterprise Tech, and Social Impact Enterprise, through a rigorous interdisciplinary curriculum, designed by industry veterans & experts. The Foundry’s well-architected framework nurtures durable and scalable […]

    The post The CoWrks Foundry concludes its first cohort appeared first on CRN - India. Reported by CRN 3 hours ago.

    0 0

    John Nordeen and Kay Lee lost touch after serving in the Vietnam War. They recall how, decades later, they reconnected. "John, we were so lucky," Lee said. "We survived Vietnam and we're still here." Reported by NPR 2 hours ago.

    0 0

    The reasons for the tragic rate of service people and veterans killing themselves are surrounded by myth. Understanding the truth is critical to finding solutions. Reported by Brisbane Times 23 hours ago.

    0 0

    'I don't think it necessarily affects us, where he shows up to anyway ceremonial fashion' Reported by Daily Caller 21 hours ago.

    0 0

    Muller and Hummels still important for Germany, says Low Joachim Low praised Thomas Muller's selflessness on the eve of his 100th Germany cap and reaffirmed his faith in the squad's veterans. Reported by Goal.com 20 hours ago.

older | 1 | .... | 1326 | 1327 | (Page 1328) | 1329 | 1330 | .... | 1362 | newer